BioSyn’s Halt in Cancer Drug Production: The Cost Factor and Market Consequences Explained by Managing Director Andreas Meyer

The pharmaceutical manufacturer BioSyn in Fellbach (Rems-Murr district) near Stuttgart had to stop producing a cancer drug some time ago after the manufacturing costs became too high. As a result, there was a shortage in the market. Even the political measures did not change this. Managing director Andreas Meyer explains why.